January 23rd 2024
Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
December 26th 2023
Reactivation of Hepatitis B After Ruxolitinib for MPN Hinges on Antivirals
July 24th 2021The issue of reactivating hepatitis B and other chronic viruses such as herpes zoster after treatment for myeloproliferative neoplasms (MPN) is an emerging issue in hematologic malignancies, due to the power of newer therapies.
Read More
Receiving Ruxolitinib Post Transplant Improves Survival Among Patients With Myelofibrosis
July 22nd 2021A study abstract presented at the European Hematology Association annual meeting found that, in a real-world setting, ruxolitinib resulted in prolonged survival among patients receiving the treatment following an allogeneic hematopoietic cell transplant.
Read More
Early Initiation of Ruxolitinib Reduces Risk, Severity of aGVHD
June 3rd 2021The study of 57 patients with acute graft-versus-host disease (aGVHD) also showed that patients tolerated the treatment, offering promise for preventing and managing the complication of transplantation, which affects up to half of patients.
Read More
Real-world Evidence Supports Conditional Use of IV Formula in Hospitalized Infants With MSUD
May 16th 2021Hospitalized infants with the rare metabolic disorder maple syrup urine disease (MSUD), who are intolerant to oral or enteral administration of branched-chain amino acid-free formula, may benefit from an intravenous formulation.
Read More
Complications of Steroid Use in GVHD Associated With Higher Health Care Usage, Costs
May 7th 2021For patients with acute and chronic graft-vs-host disease (GVHD), systemic treatment with steroids is the standard of care, and although steroid-related complications are common, the associated health care resource utilization and costs are not well documented.
Read More
Novel Approaches to Treating Polycythemia Vera Needed, Say Researchers
April 29th 2021The current treatment landscape of polycycthemia vera (PV) hinges on treatments like hydroxyurea and ruxolitinib, the latter having emerged as an effective second-line therapy in patients with severe pruritis, symptomatic splenomegaly, or post-PV myelofibrosis symptoms.
Read More
Assessing Best Practices in Managing Pregnancy, Myeloproliferative Neoplasms
April 24th 2021Researchers discuss the unique fetal and maternal challenges for pregnant women with myeloproliferative neoplasms, with insight and recommendations provided on the potential benefit of aspirin therapy, cytoreductive therapy, and systemic anticoagulation.
Read More